This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) is funding research at the University of Delaware to investigate the impact of the histone methyltransferase MET-2 (the C. elegans homolog of human SETDB1) on mitochondrial morphology, function, and protein abundance. The $155,559 award, effective June 17, 2025 through May 31, 2026, will utilize genome-edited C. elegans strains, advanced imaging, and quantitative proteomics to define MET-2's effects on mitochondria. The goal is to better understand how altered SETDB1 activity contributes to the pathogenesis of rare diseases like Huntington's, Duchenne muscular dystrophy, acute myeloid leukemia, and mesothelioma where mitochondrial dysfunction is a key factor. This basic science research could have significant impact on translating these findings to improve treatments for these conditions.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $155.6k | 6/17/25 |